Artículos por temáticas

Effects of the cognitive stimulation therapy based on Roy's adaptation model on Alzheimer's patients' cognitive functions, coping-adaptation skills, and quality of life: A randomized controlled trial

Lok N, Buldukoglu K, Barcin E.

Perspect Psychiatr Care. 2020 Jul;56(3):581-592. doi: 10.1111/ppc.12472. Epub 2020 Jan 12.

Recent Advances in Nanotechnology: A Novel Therapeutic System for the Treatment of Alzheimer's Disease

Chauhan PS, Yadav D, Koul B, Mohanta YK, Jin JO.

Curr Drug Metab. 2020;21(14):1144-1151. doi: 10.2174/1389200221666201124140518.

Undiscovered Roles for Transthyretin: From a Transporter Protein to a New Therapeutic Target for Alzheimer's Disease

Gião T, Saavedra J, Cotrina E, Quintana J, Llop J, Arsequell G, Cardoso I.

Int J Mol Sci. 2020 Mar 18;21(6):2075. doi: 10.3390/ijms21062075.

One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults

Martinez AI, Abner EL, Jicha GA, Rigsby DN, Eckmann LC, Huffmyer MJ, Moga DC.

J Manag Care Spec Pharm. 2020 Apr;26(4):520-528. doi: 10.18553/jmcp.2020.26.4.520.

Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors

Ren SY, Wang ZZ, Zhang Y, Chen NH.

Acta Pharmacol Sin. 2020 Oct;41(10):1263-1271. doi: 10.1038/s41401-020-0385-7. Epub 2020 Mar 18.

Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules

Miller JH, Das V.

Curr Pharm Des. 2020;26(35):4362-4372. doi: 10.2174/1381612826666200621171302.

Mitochondrial calcium uniporter as a potential therapeutic strategy for Alzheimer's disease

Venugopal A, Iyer M, Balasubramanian V, Vellingiri B.

Acta Neuropsychiatr. 2020 Apr;32(2):65-71. doi: 10.1017/neu.2019.39. Epub 2019 Dec 26.

Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial)

Li D, Mielke MM, Bell WR, Reilly C, Zhang L, Lin FV, Yu F.

Trials. 2020 Jan 6;21(1):19. doi: 10.1186/s13063-019-3798-1.

The impact of a multi-domain intervention on cerebral glucose metabolism: analysis from the randomized ancillary FDG PET MAPT trial

Delrieu J, Voisin T, Saint-Aubert L, Carrie I, Cantet C, Vellas B, Payoux P, Andrieu S.

Alzheimers Res Ther. 2020 Oct 19;12(1):134. doi: 10.1186/s13195-020-00683-6.

Editorial: Searching for the Holy Grail Will Need Biomarkers

Ramirez A.

J Prev Alzheimers Dis. 2020;7(1):4-6. doi: 10.14283/jpad.2020.2.

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks

Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, Dolton M, Carrasco-Triguero M, Lian Q, Bittner T, Clayton D, Smith J, Ostrowitzki S.

J Alzheimers Dis. 2020;76(3):967-979. doi: 10.3233/JAD-200134.

Alternatives to amyloid for Alzheimer's disease therapies-a symposium report

Cable J, Holtzman DM, Hyman BT, Tansey MG, Colonna M, Kellis M, Brinton RD, Albert M, Wellington CL, Sisodia SS, Tanzi RE.

Ann N Y Acad Sci. 2020 Sep;1475(1):3-14. doi: 10.1111/nyas.14371. Epub 2020 May 29.

Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer's Disease

Zhang Y, Zhao Y, Zhang J, Yang G.

Neurochem Res. 2020 Nov;45(11):2560-2572. doi: 10.1007/s11064-020-03121-z. Epub 2020 Sep 14.

Examining the benefits and harms of Alzheimer's disease screening for family members of older adults: study protocol for a randomized controlled trial

Fowler NR, Head KJ, Perkins AJ, Gao S, Callahan CM, Bakas T, Suarez SD, Boustani MA.

Trials. 2020 Feb 19;21(1):202. doi: 10.1186/s13063-019-4029-5.

A social dancing pilot intervention for older adults at high risk for Alzheimer's disease and related dementias

Blumen HM, Ayers E, Wang C, Ambrose AF, Verghese J.

Neurodegener Dis Manag. 2020 Aug;10(4):183-194. doi: 10.2217/nmt-2020-0002. Epub 2020 Aug 3.